Forgot Password?
Return to Course Listing

CME: Identification and management moderate-to-severe psoriatic arthritis: stopping the disease in its tracks and meeting unmet needs


Activity Description / Statement of Need:

Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may be associated with permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Globally, it affects 0.1-1% of people, it is a common comorbidity of patients with psoriasis, affecting up to a quarter of those with moderate-to-severe disease. affecting them in a quarter percent of the U.S. population. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible. In all, patients with PsA incur about four times the direct medical costs as compared to the average medical patient.

This accredited educational activity identifies the critical components of the management process and offer solutions to close gaps in diagnosis and care, with the ultimate goals being the improvement of psoriatic arthritis management, treatment adherence, and health and cost outcomes. 

Target Audience:

The following HCPs: rheumatologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in rheumatology and immunology; and any other HCPs with an interest in or who clinically encounter patients with PsA.


This activity is supported in part  by an independent medical educational grant from Mylan Inc., a Viatris Company

This activity is free of charge.

Release Date: May 15, 2022 -- Expiration Date: May 15, 2024

Faculty: Peng Fan, MD


Faculty introduction, disclosures

Introduction content: cursory refresher and review of PsA

  Epidemiology: statistics by severity


  Clinical presentation; disease progression; complications, comorbidities, and burden of disease

  Evaluation, diagnosis, and associated pitfalls

Treatment of PsA

  Peripheral arthritis vs. axial disease


  Moderate-to-severe disease treatment

  cDMARDs: methotrexate, leflunomide, and phosphodiesterase-4 inhibition

  Adverse prognosis and resistance to cDMARDs

  Tumor necrosis factor-targeting therapy

  IL-17, -12, and -23-targeting therapies

  Selective T-cell costimulation

  Janus kinase inhibition

  Later-line agents


  Recent clinical trial evidence and guideline updates

  Emerging and future therapies

  Disease flares and adverse events

  Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall barriers to optimal care in patients with PsA, including the burden of disease, consequences of delayed diagnosis, and suboptimal therapy
  • Describe guideline-recommended and investigational pharmacotherapy for moderate-to-severe PsA
  • Formulate a treatment plan for a patient with moderate-to-severe PsA


ACCME Activity #202290043


Faculty Disclosure and Resolution of COI

As a provider of continuing healthcare education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME/CPE activity. For this CME/CPE activity, any COI has been resolved thru content review ScientiaCME.

Faculty: Peng Fan M.D. FACP, Clinical Professor of Medicine, Division of Rheumatology,David Geffen School of Medicine at UCLA, has received financial compensation from Amgen, Pfizer, Abbvie, Sanofi, Novartis, Radius, and Regeneron for speaker's bureau work.


Faculty WILL discuss off-label use of a commercial product.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This activity is supported in part  by an independent medical educational grant from Mylan Inc., a Viatris Company


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.